A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue

Trial Profile

A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Breast cancer; Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Sep 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 11 Sep 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
    • 11 Sep 2013 Planned End Date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top